Medicine and Dentistry
Patient
100%
Docetaxel
87%
Diseases
25%
Toxicity
25%
Transitional Cell Carcinoma
25%
Platinum
25%
Overall Survival
12%
Adverse Event
12%
Disease Exacerbation
12%
Progression Free Survival
12%
Drug Dose Regimen
12%
Neutropenia
12%
Pharmacology, Toxicology and Pharmaceutical Science
Docetaxel
87%
Second-Line Chemotherapy
50%
Diseases
25%
Toxicity
25%
Platinum
25%
Transitional Cell Carcinoma
25%
Chemotherapy
25%
Adverse Event
12%
Overall Survival
12%
Disease Exacerbation
12%
Neutropenia
12%
Progression Free Survival
12%
Neuroscience
Docetaxel
87%
Chemotherapy
37%
Immunology and Microbiology
Overall Survival
12%
Progression Free Survival
12%
Drug Dose Regimen
12%
Biochemistry, Genetics and Molecular Biology
Progression Free Survival
12%
Overall Survival
12%
Drug Dose Regimen
12%